CN Patent

CN105007920A — 雄激素受体调节剂及其用途

Assigned to Aragon Pharmaceuticals Inc · Expires 2015-10-28 · 11y expired

What this patent protects

本发明描述了与其它治疗选择组合的式(I)的雄激素受体调节剂用于治疗前列腺癌和用于治疗适合于使用雄激素受体调节剂治疗的疾病或病症以及包含这种化合物的药物组合物和药物。

USPTO Abstract

本发明描述了与其它治疗选择组合的式(I)的雄激素受体调节剂用于治疗前列腺癌和用于治疗适合于使用雄激素受体调节剂治疗的疾病或病症以及包含这种化合物的药物组合物和药物。

Drugs covered by this patent

Erleada (apalutamide) · Johnson & Johnson

Patent Metadata

Patent number: CN105007920A
Jurisdiction: CN
Classification: —
Expires: 2015-10-28
Drug substance claim: No
Drug product claim: No
Assignee: Aragon Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.